| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | bendamustine | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.6 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |